Compare Novo Nordisk A/S (NVO) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs OneSpan Inc — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while OneSpan Inc trades at $18.22 (market cap $662.97M). The key difference: Novo Nordisk A/S is far larger — about 249.3× OneSpan Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and OneSpan Inc for 18 Days on average.
| NVO | OSPN | |
|---|---|---|
Market Cap | $165.31B | $662.97M |
Volume | 11,432,838 | 616,882 |
Sector | Health | Technology |
52-Week High | $63.98 | $18.42 |
52-Week Low | $35.29 | $10.15 |
Typical Hold Time | 116 Days | 18 Days |
Enterprise Value | $179.56B | $632.05M |
Dividend Yield | 4.71% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
OneSpan (OSPN) trades at $18.01, up 1.75% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with a 27.76% net margin and consistent earnings beats, though 2026 projections show slight margin compression. Recent product innovation with DigipassONE and institutional interest from Deutsche Bank highlight growth potential amid competitive pressures.
Outlook remains positive with 67% analyst buy ratings and attractive valuation at 10.16 P/E, but investors face risks from subscription transition execution and market volatility. The stock's current technical positioning near key resistance at $19 requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
